WO2025021148 - WRN INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/021148
Publication Date
30.01.2025
International Application No.
PCT/CN2024/107526
International Filing Date
25.07.2024
Title **
[English]
WRN INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
[French]
INHIBITEUR DE WRN, COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET UTILISATION ASSOCIÉE
[Chinese]
WRN抑制剂及其药物组合物和应用
Applicants **
BETTA PHARMACEUTICALS CO., LTD
Inventors
ZHANG, Jian
SUN, Yun
FU, Bang
CHEN, Jie
MA, Teng
GAO, Jinheng
WANG, Dongyang
RONG, Hongfei
LI, Yinlong
SHEN, Qichao
BAI, Jinlong
RAO, Yin
WANG, Chao
SONG, Xiaodong
XU, Xiaofeng
LIU, Xiangyong
BAI, Ying
LIU, Xiaoyun
ZHANG, Yongchun
GUO, Jing
LAN, Hong
DING, Lieming
WANG, Jiabing
Priority Data
PCT/CN2023/109682
27.07.2023
CN
PCT/CN2023/125390
19.10.2023
CN
202410764276.0
13.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3811 | |
| EPO | Filing, Examination, Granting | 28657 | |
| Japan | Filing, Examination, Granting | 2885 | |
| South Korea | Filing, Examination, Granting | 3682 | |
| USA | Filing, Examination, Granting | 9690 |
Total:
48,725
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A WRN inhibitor, and a composition and the use thereof. Particularly, a compound as represented by formula (I), a pharmaceutical composition containing same and the use thereof as a WRN inhibitor in the treatment of cancer-related diseases.[French]
L'invention concerne un inhibiteur de WRN, une composition et son utilisation. En particulier, l'invention concerne un composé tel que représenté par la formule (I), une composition pharmaceutique le contenant et son utilisation en tant qu'inhibiteur de WRN dans le traitement de maladies associées au cancer.[Chinese]
WRN抑制剂、组合物及其应用。特别地，式（I）所示的化合物、含有该化合物的药物组合物，及其作为WRN抑制剂在治疗癌症相关疾病中的用途。